

Colorectal cancer is a common type of cancer that affects the colon or rectum and often develops gradually, sometimes without noticeable symptoms in the early stages. Early detection plays a critical role in improving outcomes, as treatment is more effective when the disease is identified at an early or localized stage.
The Cancer Marker Profile - Colorectal is a focused panel that evaluates tumor markers and gastrointestinal bleeding that may be associated with colorectal cancer. This panel includes the CEA (carcino embryonic antigen) test, which is a well-established marker in colorectal cancer care, primarily used to assess tumor burden, monitor response to treatment, and detect recurrence, though it has limited sensitivity for early diagnosis and may be elevated in smokers or benign conditions, such as inflammatory bowel disease, pancreatitis, liver disease (including cirrhosis), hepatitis, and chronic obstructive pulmonary disease (COPD), which can limit its specificity for cancer detection..
CA 19.9 supports the assessment of gastrointestinal malignancies and is useful for monitoring disease progression or treatment response, but it lacks specificity for colorectal cancer and is not suitable as a standalone screening test. Levels may also be elevated in benign conditions such as pancreatitis, cholestasis, and liver disease, and some individuals (Lewis antigen–negative) do not produce CA 19.9, which can lead to false-negative results
In addition, the Stool for Occult Blood test detects hidden (microscopic) blood in stool, which can be an early sign of colorectal tumors or polyps. However, the test does not identify the exact source of bleeding and may also be positive in benign conditions such as hemorrhoids, gastrointestinal inflammation, or ulcers. Additionally, certain foods (e.g., red meat, turnips, radishes, broccoli, cauliflower) and some medications may cause false-positive results, so these are often advised to be avoided before sample collection.
A doctor may suggest this panel for individuals undergoing evaluation for colorectal cancer risk, those with suspicious gastrointestinal findings, or patients requiring baseline or follow-up monitoring during or after cancer treatment.
For this test, provide a brief clinical history or doctor’s prescription at the time of sample collection. For stool occult blood, collect a fresh stool sample in a clean, sterile, leak-proof screw-capped container, taking only a small portion (5–10 g or 1–2 teaspoons) without overfilling. Do not use paper, matchboxes, or absorbent materials, and avoid contamination with urine or water. Avoid painkillers, iron tablets, vitamin C (ascorbic acid), and hard toothbrush use for 3 days before sample collection. Red meat and raw vegetables such as broccoli, cauliflower, radish, and turnip should also be avoided during this period.
Test results should always be interpreted by a doctor along with clinical findings, imaging studies, and, if required, endoscopic evaluation. Based on the results, further diagnostic tests or follow-up monitoring may be recommended.
The Cancer Marker Profile - Colorectal measures tumor-associated markers and gastrointestinal bleeding indicators relevant to colorectal cancer. Carcinoembryonic Antigen (CEA) helps assess tumor burden and monitor treatment response in many patients with colorectal cancer. CA 19-9 provides supportive information related to gastrointestinal malignancies. Stool for Occult Blood detects microscopic blood loss from the gastrointestinal tract, which may indicate colorectal lesions. Together, these parameters provide a complementary overview of colorectal health; however, none are diagnostic on their own, and results must be interpreted in conjunction with clinical evaluation, imaging, colonoscopy, and patient risk factors. When used appropriately, the Cancer Marker Profile - Colorectal supports timely clinical decision-making and disease surveillance.
The Stool For Occult Blood test measures the presence of occult (hidden) blood in the stool, which cannot be seen with naked eyes. This test helps detect small amounts of blood that may be indicative of various gastrointestinal conditions such as colorectal cancer, diverticular disease, polyps, inflammatory bowel disease etc. By identifying even trace amounts of blood, it can help detect bleeding within the digestive tract that may indicate a significant underlying condition warranting further investigation.
The Stool For Occult Blood test helps in the early identification of the underlying problem causing bleeding, potentially preventing the complications and improving the treatment outcome.
Know more about Stool For Occult Blood
A CA19.9 test measures the level of a specific tumor marker called CA 19.9 in the blood, often associated with gastrointestinal cancers, particularly pancreatic cancer. This biomarker is produced by certain cells in the body, specifically epithelial cells. These cells are found in various tissues, including the gastrointestinal tract. Elevated levels of CA 19.9 are often associated with cancers that involve these tissues, such as pancreatic, colorectal, and gastric cancers. However, CA 19.9 can also be produced by non-cancerous conditions, impacting its specificity as a diagnostic marker. For a comprehensive evaluation, it is advised to consider other diagnostic tests in conjunction with a CA19.9 test and consult a doctor for a proper understanding of the test results.
Know more about CA19.9
The Cancer Marker Profile - Colorectal is done to:
- Support clinical evaluation and early detection of colorectal cancer when used along with other tests
- Evaluate tumor markers associated with colorectal malignancies
- Detect hidden blood in stool linked to gastrointestinal bleeding
- Monitor disease progression or treatment response, particularly by using CEA levels
- Assist in follow-up and recurrence surveillance
- For CA 19.9 and CEA: Provide brief clinical history/doctor's prescription at the time of sample collection.
- For stool for occult blood: Collect a fresh stool sample in a clean, sterile, leak-proof screw-capped container (preferably with a spoon). Take only a small portion (5-10 grams or 1–2 teaspoons). Do not overfill. Do not use matchboxes, paper, or other absorbent materials. Avoid contamination with urine or water. Avoid pain killers, iron tablets, Vitamin C (Ascorbic Acid) and hard tooth brush for 3 days prior to specimen collection. Meat products, especially red meat, as well as raw broccoli, cauliflower, radish, and turnip should also be avoided.






























